Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation. - Wikidata - awgldk - TriplyDB

Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation.

Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation.

http://www.wikidata.org/entity/Q33752154

about

Nanomolar-Potency Aminophenyl-1,3,5-triazine Activators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel for Prosecretory Therapy of Dry Eye Diseases.Luminally Acting Agents for Constipation Treatment: A Review Based on Literatures and Patents.High-Potency Phenylquinoxalinone Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activators.

P2860

Q33752165-D86FC2B2-D909-48AB-A3CC-0F995A16CAA9 Q33854983-C317AEED-059A-48F1-A71C-C97F7503E8A3 Q38715239-F0188710-A9B0-44CE-8A13-3A68CBCF965D

P2860

Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation.

http://www.wikidata.org/entity/Q33752154

description

2016 nî lūn-bûn

@nan

2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation.

@ast

Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation.

@en

type

label

Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation.

@ast

Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation.

@en

prefLabel

Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation.

@ast

Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation.

@en

P1433

Q33752154-EC4BD2F0-634F-41C0-8592-6EDF7B96B7E8

P1476

Q33752154-C57261DC-F83A-4B3D-B990-ABCE93C51FC4

P2093

Q33752154-10650C3F-0DC4-4769-813E-FD0BCBAD72A4

Q33752154-1DF1C2E5-150C-47A0-858D-57F4F0B7D9F8

Q33752154-4468062A-1057-4258-92F4-FFB5CED41F7C

Q33752154-4D8D3A6F-4E65-43C2-A43B-1A4A4A2301EF

Q33752154-53A12539-EB32-40BE-A97F-4C9785288D4C

Q33752154-53E14C6B-CC13-460A-ADA3-4BCAF231B2C2

Q33752154-5A33E332-A80E-4B99-8ED4-376012A56174

Q33752154-7FA228DD-07F7-4844-8FA0-A8E648288066

Q33752154-819B8541-4824-44E3-8C52-8DE9CD4BD9D1

Q33752154-AE0EA144-9281-4AA7-8F7B-735B019CCDEA

P2860

Q33752154-000AC2D2-E051-494D-86BD-6C449C27D356

Q33752154-01BD4D8B-FA3C-40C7-BC71-E73A2BFF9BD7

Q33752154-05807AD0-1477-4CF3-96C8-7D0FFECFA776

Q33752154-0EF0C4AA-F611-48F4-9FF6-C5FFC05A7526

Q33752154-13053FA2-B6BB-4ED2-A368-8C50AB8CD22E

Q33752154-2B4A9E1F-B4DB-4F17-AF5C-655AD28DB13E

Q33752154-2E1C09B0-D68A-4BBD-8625-19231D3A985E

Q33752154-56506B05-00FE-423C-A7B5-79B946AB2262

Q33752154-60FD4240-D41E-4B68-AE9F-2A1CC6FB7250

Q33752154-641B52A9-8A97-4055-A897-66FC73D19BB7

P304

Q33752154-27BF6DAB-0EF2-405E-895A-04F3115DBCD6

P31

Q33752154-5D58185E-504A-4C2D-BE5F-0FF7B2086DDD

P356

Q33752154-36BDD301-020B-4FA1-8BD7-07A2FF653342

P478

Q33752154-9D9D29CC-2F2B-4DCF-8E57-93D5458BBD4A

P577

Q33752154-E3D2ED6F-D786-4957-AF2C-A31D63317C24

P698

Q33752154-473D4D52-E2B3-406D-AB25-CB574CC43237

P932

Q33752154-06968D46-8C3F-4F3F-BDA9-AA5D9A8B3B75

P356

J.TRSL.2016.10.003

P1433

Translational Research

P1476

Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation.

@en

P2093

Alan S Verkman

http://www.w3.org/2001/XMLSchema#string

Andrew P Teuthorn

http://www.w3.org/2001/XMLSchema#string

Colton K Ku

http://www.w3.org/2001/XMLSchema#string

Jie S Zhu

http://www.w3.org/2001/XMLSchema#string

Jung-Ho Son

http://www.w3.org/2001/XMLSchema#string

Loretta Ferrera

http://www.w3.org/2001/XMLSchema#string

Luis J V Galietta

http://www.w3.org/2001/XMLSchema#string

Mark Donowitz

http://www.w3.org/2001/XMLSchema#string

Mark J Kurth

http://www.w3.org/2001/XMLSchema#string

Nicholas C Zachos

http://www.w3.org/2001/XMLSchema#string

P2860

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

A functional CFTR assay using primary cystic fibrosis intestinal organoids

Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds.

Human Enteroids as a Model of Upper Small Intestinal Ion Transport Physiology and Pathophysiology.

Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse.

Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner.

Molecular properties that influence the oral bioavailability of drug candidates.

Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice.

Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.

Effect of cholera enterotoxin on ion transport across isolated ileal mucosa.

P304

14-26.e4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TRSL.2016.10.003

http://www.w3.org/2001/XMLSchema#string

P478

182

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27815136

http://www.w3.org/2001/XMLSchema#string

P932

5453637

http://www.w3.org/2001/XMLSchema#string